Literature DB >> 3415201

Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism.

J I Sage1, S Trooskin, P K Sonsalla, R Heikkila, R C Duvoisin.   

Abstract

We report the long-term clinical responses of 2 parkinsonian patients with severe "on-off" phenomena who have been receiving continuous duodenal levodopa (LD) infusions. The rate of LD infusion needed to keep the patients just "on" declined gradually during the initial 60 days of infusion and then remained constant. Total LD intake declined rapidly during the first several days and gradually for another 60 days, after which it remained stable. Motor fluctuations virtually disappeared in both patients during the time of the day when the pump was in use. This was accompanied by a decline in the plasma LD concentration needed to just maintain the "on" stage in one patient.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3415201     DOI: 10.1002/ana.410240116

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

Review 1.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 2.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 3.  Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.

Authors:  M C Kurth
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 4.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

5.  Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.

Authors:  E Bredberg; D Nilsson; K Johansson; S M Aquilonius; B Johnels; C Nyström; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations.

Authors:  M J Steiger; T El-Debas; T Anderson; L J Findley; C D Marsden
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

Review 7.  Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities.

Authors:  A J Hughes
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

8.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Authors:  C Warren Olanow; Karl Kieburtz; Per Odin; Alberto J Espay; David G Standaert; Hubert H Fernandez; Arvydas Vanagunas; Ahmed A Othman; Katherine L Widnell; Weining Z Robieson; Yili Pritchett; Krai Chatamra; Janet Benesh; Robert A Lenz; Angelo Antonini
Journal:  Lancet Neurol       Date:  2013-12-20       Impact factor: 44.182

9.  Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease.

Authors:  Erik Cederfjäll; Lauren Broom; Deniz Kirik
Journal:  Mol Ther       Date:  2015-01-16       Impact factor: 11.454

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.